Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

E55: Anifrolumab for SLE (TULIP 1&2)

E55: Anifrolumab for SLE (TULIP 1&2)

FromThe Evidence Based Rheumatology Podcast


E55: Anifrolumab for SLE (TULIP 1&2)

FromThe Evidence Based Rheumatology Podcast

ratings:
Length:
18 minutes
Released:
Jan 23, 2020
Format:
Podcast episode

Description

This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE.  Great to see a new drug in this disease state; interesting to think through how these trials played out.  Get the papers and the pod at ebrheum.com and follow me @ebrheum if you'd like to share feedback! 
Released:
Jan 23, 2020
Format:
Podcast episode

Titles in the series (87)

A weekly podcast for physicians interested in evidence based medicine and rheumatology. Find the papers at ebrheum.com